The present disclosure is directed to novel derivatives of terpenes, particularly ester derivatives of terpene alcohols, and methods of making them, compositions comprising them, and methods for using them.

The present disclosure is directed to novel derivatives of terpenes, particularly ester derivatives of terpene alcohols, and methods of making them, compositions comprising them, and methods for using them.

Biologically active cannabidiol analogs comprising a compound of the formula ##STR00001##
wherein one of R.sub.1 or R.sub.2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R.sub.1 or R.sub.2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R.sub.1 or R.sub.2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Biologically active cannabidiol analogs comprising a compound of the formula ##STR00001##
wherein one of R.sub.1 or R.sub.2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R.sub.1 or R.sub.2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R.sub.1 or R.sub.2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

The object of the present invention is to provide a mitochondrial dysfunction improving agent comprising a vitamin K derivative having a high deliverability to mitochondria.

A mitochondrial dysfunction improving agent, neurodegeneration improving agent, amyotrophic lateral sclerosis improving agent, Alzheimer's disease improving agent, and Parkinson's disease improving agent comprising at least one of a carboxylic acid ester of an active vitamin K represented by a general formula (1) or a salt thereof, and

##STR00001##

(wherein, R.sub.1 and R.sub.2 are a hydrogen atom, respectively, or a substituent selected from glycine, N-acyl glycine, N-alkyl glycine, N,N-dialkyl glycine, N,N,N-trialkyl glycine, acyl, dicarboxylic acid hemiester, and salts thereof; and at least either of R.sub.1 and R.sub.2 is glycine, N-acyl glycine, N-alkyl glycine, N,N-dialkyl glycine, N,N,N-trialkyl glycine, acyl, dicarboxylic acid hemiester, and salts thereof. R.sub.3 is a group represented by a general formula (2), or a general formula (3). n is an integer of 1 to 7)

##STR00002##

a mitochondrial dysfunction improving agent, neurodegeneration improving agent, amyotrophic lateral sclerosis improving agent, Alzheimer's disease improving agent, and Parkinson's disease improving agent comprising a carboxylic acid ester of an active vitamin K or a salt thereof (in the general formula (1), R.sub.1 and R.sub.2 is a carboxylic acid residue selected from a group consisting of R.sub.4OOCCH.sub.2CH.sub.2CO— and R.sub.4OOCCH.sub.2CH.sub.2CH.sub.2CO—. R.sub.3 represents the above general formula (2) or (3). R.sub.4 is a C1-C3 alkyl group.).

The present invention relates to compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof. The present compound is represented by Formula (II), which has the formula: R.sub.1—O—X—(CH.sub.2).sub.m—X—O—R.sub.2, wherein: each X is —C(═O)—; R.sub.1 is a C.sub.1-C.sub.18 alkyl polyol; R.sub.2 is a saccharide group of formula (G).sub.p; G is a monosaccharide residue, where (i) at least one of the —OH groups in (G).sub.p is substituted by a halogen atom, and (ii) the saccharide group of formula (G).sub.p is linked to —O— through a —CH.sub.2 group; p is 1 or 2; and m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

The present invention relates to compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof. The present compound is represented by Formula (II), which has the formula: R.sub.1—O—X—(CH.sub.2).sub.m—X—O—R.sub.2, wherein: each X is —C(═O)—; R.sub.1 is a C.sub.1-C.sub.18 alkyl polyol; R.sub.2 is a saccharide group of formula (G).sub.p; G is a monosaccharide residue, where (i) at least one of the —OH groups in (G).sub.p is substituted by a halogen atom, and (ii) the saccharide group of formula (G).sub.p is linked to —O— through a —CH.sub.2 group; p is 1 or 2; and m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

The invention provides a novel hydrocarbon-containing carboxylic acid, hydrocarbon-containing sulfonic acid, hydrocarbon-containing sulfuric acid ester, or a salt thereof, and a surfactant. Each of them is a compound represented by the following formula (1):
CR.sup.1R.sup.2R.sup.4—CR.sup.3R.sup.5—X-A
wherein R.sup.1 to R.sup.5 are each H or a monovalent substituent; at least one of R.sup.1 or R.sup.3 is a group represented by the formula: —Y—R.sup.6; at least one of R.sup.2 or R.sup.5 is a group represented by the formula: —X-A or a group represented by the formula: —Y—R.sup.6; and As at the respective appearances are the same as or different from each other, and are each —COOM, —SO.sub.3M, or —OSO.sub.3M.

This invention relates to the field of plastic waste decomposition. More specifically, the invention comprises products obtained from the decomposition of plastic waste.

This invention relates to the field of plastic waste decomposition. More specifically, the invention comprises products obtained from the decomposition of plastic waste.